The Non-Financial Ledger

The people who bought Tru Niagen were not reckless. They were careful. According to the complaint, plaintiff Caryn Hart “cares about her long-term health and consciously takes preventative measures to increase her wellness and longevity.” That care is exactly what the marketing targeted. The product spoke directly to the private fear of getting older and losing your body, then promised science had solved it.

Each of the three plaintiffs describes the same quiet letdown. They read the “clinically proven” language, they paid more than they would have for a generic supplement, they took the pills every day as instructed, and then, in the words repeated across all three accounts, they “felt none of the promoted health benefits” and stopped. The betrayal here is not dramatic. It is the slow realization that a trusted-sounding word was doing work it had no right to do.

The complaint frames this as the newest version of an old scheme: “‘Snake oil’ salesmen scams are some of the oldest tricks in the book.” The harm is the exploitation of a deeply personal anxiety about mortality, dressed up in the vocabulary of laboratories and clinical trials.

Legal Receipts

The complaint quotes the company’s own marketing and the findings of the review bodies that examined it. These are the words on the record.

“clinically proven to significantly increase NAD+ levels, and help maintain them with daily use”

• This is the central establishment claim the plaintiffs say misled them, presented as settled science rather than limited, condition-dependent findings.
• The complaint alleges consumers read “clinically proven” to mean effectiveness “broadly supported by the scientific community.”

“A COMPLETE ANTI AGING SUPPLEMENT” supporting “brain health, muscle health and recovery, heart health, cellular energy and repair”

• This Amazon listing language, per the complaint, appeared “immediately following a ‘clinically proven’ establishment claim.”
• The complaint states these were “the precise health-benefit categories the NARB determined were unsupported.”

An influencer discussed how health guru Bryan Johnson uses the Products to “get his NAD+ levels equal to that of a 16-year-old.”

• This TikTok, posted March 23, 2026, was “viewed over 170,000 times as of June 4, 2026,” illustrating the reach of influencer promotion.
• The complaint alleges the company distributes its claims to influencers for promotional content.

Public Deception: The Word Doing the Heavy Lifting

The heart of the case is the gap between the phrase “clinically proven” and what the underlying science actually showed.

• The company claimed the Products were “clinically proven to significantly increase NAD+ levels.” The National Advertising Division found the active ingredient NR “was found to only increase NAD+ levels under certain limited conditions,” with outcomes varying by study design, population, and duration.
• The company claimed NAD+ levels “rise within hours and show significant increase within two weeks.” The review bodies concluded the cited studies did not support the broad clinically-proven message conveyed to consumers.
• The company linked biomarker increases to real health benefits. The NARB “determined that Defendants’ advertising improperly conveyed that biomarker increases from taking the Products translated to real-world health and anti-aging benefits.”
• The company promoted cellular and organ-health claims. The National Advertising Division clarified these “could reasonably convey to a consumer that the Products are meant to provide tangible, functional health benefits” that the science did not establish.

Profit-Maximization at All Costs

The complaint documents a business model built on charging a premium for a word the science did not earn.

• The company charges approximately $50 per 30-count bottle, with 90-count and 180-count bottles retailing around $127.00 and $244.00.
• The complaint alleges the company is “aware that consumers are willing to pay a premium for products that claim they are ‘clinically proven’ to work.”
• The company “touted in 2024 to have sold over 8 million units of the Products globally.”
• This sits inside a NAD+ supplement market “valued at $252 million in 2024 and projected to reach $884 million by 2034.”
• The complaint alleges the health claims were “the centerpiece of their marketing campaign,” meaning the disputed language was the engine of the premium price.

How the Watchdog Was Answered: A Timeline of Delay

The complaint documents an accountability process the company contested at each stage while continuing to sell.

• A competitor, Reus Research LLC, challenged the claims, triggering a National Advertising Division review that found the “clinically proven” claims unsupported.
• The company “voluntarily agreed to discontinue certain challenged claims,” including reproductive health, sleep improvement, and “Made in USA” claims.
• The complaint alleges that “as of June 5, 2026, claims that the Products improve reproductive health are still shown on Defendants’ website,” despite that agreement.
• Rather than accept the finding, the company “appealed the National Advertising Division’s decision to the National Advertising Review Board.”
• On May 21, 2026, the NARB affirmed the decision, agreeing the cited studies did not support the “clinically proven” health-benefit claims.

Manufactured Consent: The Influencer Machine

The complaint documents how the company shaped perception through a coordinated promotional operation aimed at anxious, aspirational buyers.

• The company built “a consistent and uniform marketing campaign across their labeling, packaging, subscription programs, testimonials, social media and influencer campaigns and digital advertising.”
• The complaint alleges the company “distribute[s] to influencers” its claims for promotional content, including the “clinically proven” and anti-aging messaging.
• The National Advertising Division found “certain testimonials promoted by Defendants also conveyed unsupported messages regarding improvements in health or functional benefits.”
• The National Advertising Division recommended the company ensure “material connections between the influencers and Defendants were clearly and conspicuously disclosed,” consistent with FTC Endorsement Guides, implying they were not adequately disclosed.
• The campaign leaned on the celebrity of longevity figures like Bryan Johnson, Andrew Huberman, and Gary Brecka to lend borrowed credibility to the pill.

Societal Impact Mapping

Public Health

The core public-health harm is the substitution of a costly pill for interventions that actually work.

• The complaint notes doctors and researchers say “the best ways to increase one’s NAD+ levels are through diet and exercise changes,” not supplementation.
• Research on NAD+ supplements is “limited or inconclusive at best,” yet the marketing presented it as settled.
• The claims targeted “vulnerable consumers’ anxieties about their health declining as they age,” a group primed to trust health-coded language.
• Consumers “are also not in the position to evaluate Defendants’ health claims,” creating an information gap the marketing exploited.

Economic Inequality

The harm fell on people willing to spend more precisely because they were told the product was scientifically superior.

• Buyers paid “a premium price of approximately $50 per 30 count bottle,” far above generic supplements.
• The complaint alleges consumers “would not have purchased the Products, or at least would have paid substantially less” absent the disputed claims.
• The premium was extracted from people managing “deeply personal” fears about aging and long-term health.
• With over 8 million units sold globally in 2024, the aggregate overpayment scales across a very large consumer base.

Who Pays? Following the Cost

The complaint alleges the cost was transferred directly onto consumers through a price premium justified by unsupported science.

• The premium originated with the company’s “clinically proven” positioning and flowed to buyers as an inflated purchase price.
• Plaintiff Hart paid $44.99 plus tax for a 300mg 30-count bottle at Sprouts Farmers Market.
• Plaintiff Erslev paid $101.60 for a 300mg 90-count bottle directly from the company website.
• Plaintiff Ivey paid $40.20 for a 300mg 30-count bottle on Amazon.
• The complaint alleges class members “incurred economic damages equal to the entirety of the purchase price they paid for the Products.”

The “Cost of a Life” Metric

This Is the System Working as Intended

The structural lesson of this case is that a self-regulatory finding, on its own, did not stop the sales.

• The National Advertising Division and the NARB both ruled against the claims, yet these are industry self-regulatory bodies without the power to impose penalties, so the product kept selling.
• The complaint alleges reproductive-health claims “the company agreed to discontinue” were “still shown on Defendants’ website” weeks after the agreement, showing how voluntary commitments can go unenforced.
• The supplement market grew “from 4,000 products available in 1994 to as many as 95,000 available in 2024,” a scale that outpaces meaningful oversight.
• Because “consumers are not in the position to evaluate” clinical claims, the burden of catching deception fell on a competitor’s challenge and, ultimately, private litigation rather than a regulator.

What a Legitimate Fix Looks Like

This case exposes how the phrase “clinically proven” can be deployed without enforceable substantiation, and how self-regulatory findings lack teeth. The following are editorial recommendations, not findings of the source document.

Regulatory Track

• The FTC should treat “clinically proven” establishment claims on supplements as requiring documented, condition-matched human evidence before the label ships, with active enforcement of its Endorsement Guides on influencer disclosure identified as deficient here.
• Regulators should require that when a self-regulatory body (NAD/NARB) finds a claim unsupported, the seller must remove it within a fixed, verified window, closing the gap the complaint alleges around lingering reproductive-health claims.
• General industry standard: retailers such as Amazon, Walmart, and Target should be required to delist supplement listings after a formal unsupported-claim finding until the listing is corrected.

Legislative Track

• Legislators should functionally require pre-market substantiation for any dietary supplement that uses “clinically proven” or equivalent establishment language for a specific health outcome.
• A statutory penalty tied to units sold under an unsupported establishment claim would convert a toothless finding into a real deterrent.
• Mandatory, plain-language disclosure that “results vary by study design and are not established for all consumers” should accompany any NAD+ or longevity health-benefit claim.

Corporate Governance Track

• The company should establish an independent scientific-review sign-off, separate from marketing, before any “clinically proven” claim is published.
• Executive compensation tied to supplement sales should be clawed back when claims driving those sales are later found unsupported.
• A standing compliance function should audit live listings and influencer content against the specific claims the NARB flagged, with documented removal timelines.

What Now?

Direct your attention to the two companies named in the complaint, Niagen Bioscience, Inc. and ChromaDex, Inc., both headquartered at the same Los Angeles address, and to the regulators with power the review boards lacked.

• Watchlist: The FTC, which enforces truth-in-advertising and the Endorsement Guides the National Advertising Division cited as deficient in this case.
• Watchlist: The FDA, which oversees the dietary supplement market that grew to roughly 95,000 products by 2024.
• If you bought Tru Niagen, keep your receipts and order records; the complaint estimates class members “number in the thousands to millions” and identity may be traced through company records.
• Share verified information with friends chasing longevity trends, and treat “clinically proven” as a claim to check, not a fact to trust.
• Support local consumer-protection clinics and independent science communicators who translate limited, inconclusive research for the public rather than sell it.